Información del artículo
Ghrelin is a recently discovered peptide hormone with 28 amino acids. This hormone is mainly secreted by the stomach and to a lesser extent by the gut, pancreas, kidney, placenta, hypothalamus and pituitary gland. It is the first natural acylated peptide; it contains an n-octanoyl group at serine-3, which is essential for crossing the hematoencephalic barrier and performing its biological activity. Nevertheless 75% of circulating ghrelin is in the non-acylated form.
Among the multiple functions of ghrelin that have been identified to date, by far the most important are its growth hormonereleasing activity and its role in the regulation of energy balance. Ghrelin secretion has a circadian rhythm with an increase before each meal and a reduction after food intake. This preprandial increase may play a role in prompting food intake. This hormone is one of the most powerful orexigens acting on the arcuate nucleus of the hypothalamus. In rats ghrelin promotes weight gain by increasing adiposity and reducing fat utilization. Ghrelin levels are increased in states of negative energy balance such as fasting and anorexia nervosa and are decreased in positive states such as obesity. Therefore, together with leptin and insulin, this hormone belongs to the set of peripheral signs that informs the brain about the status of energy stores and contributes to long-term weight regulation.
Key words:
Ghrelin
Nutrition
Obesity
Growth hormone
Growth hormone synthetic secretagogues
Energy balance
Palabras clave:
Ghrelina
Nutrición
Obesidad
Hormona de crecimiento (GH)
Secretagogos sintéticos de GH
Equilibrio energético
La ghrelina es una hormona peptídica de 28 aminoácidos, recientemente descubierta, secretada en su mayor parte por el estómago y en menor proporción por el intestino, el páncreas, el riñón, la placenta, el hipotálamo y la hipófisis. Se trata del primer péptido natural acilado; tiene un grupo n-octanoil en la serina 3, que es esencial para su bioactividad, ya que le permite cruzar la barrera hematoencefálica. No obstante, el 75% de la ghrelina circula en forma no acilada.
De entre sus múltiples funciones hasta ahora conocidas destacan su actividad secretagoga de hormona de crecimiento (GH) y su papel en la regulación del equilibrio energético. La secreción de ghrelina sigue un ritmo circadiano; muestra un pico antes de cada comida y presenta una disminución de las concentraciones tras la ingesta. A este incremento preprandial se le ha atribuido un papel como señal para iniciar la ingesta. Es uno de los más potentes orexígenos conocidos y actúa en el núcleo arcuato del hipotálamo. En ratas provoca un aumento de peso a expensas de un incremento de la adiposidad y una reducción de la utilización de las grasas. Se encuentra elevada en situaciones de equilibrio energético negativo, como el ayuno o la anorexia nerviosa y disminuida en situaciones de equilibrio energético positivo, como la obesidad. Forma parte, por tanto, junto con la leptina y la insulina, del conjunto de señales periféricas que comunica el estatus de las reservas de energía al cerebro y contribuye a la regulación del peso a largo plazo.
El Texto completo está disponible en PDF
Biblografía
[1.]
M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, K. Kangawa.
Ghrelin is a growth-hormone-releasing acylated peptide from stomach.
Nature, 402 (1999), pp. 656-660
[2.]
Y. Date, M. Kojima, H. Hosoda, A. Sawaguchi, M. Mondal, T. Suganuma, et al.
Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans.
Endocrinology, 141 (2000), pp. 4255-4261
[3.]
O. Gualillo, E. Caminos, M. Blancos, T. García-Caballero, M. Kojima, K. Kangawa, et al.
Ghrelin, a novel placental-derived hormone.
Endocrinology, 142 (2001), pp. 788-794
[4.]
K. Mori, A. Yoshimoto, K. Takaya, K. Hosoda, H. Ariyasu, K. Yahata, et al.
Kidney produces a novel acylated peptide, ghrelin.
FEBS Letters, 486 (2000), pp. 231-236
[5.]
M. Korbonits, M. Kojima, A. Grossman.
Presence of ghrelin in normal and adenomatous human pituitary.
Endocrine, 14 (2001), pp. 101-104
[6.]
M. Volante, E. Allía, P. Gugliotta, A. Funaro, F. Broglio, R. Deghenghi, et al.
Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors.
J Clin Endocrinol Metab, 87 (2002), pp. 1300-1308
[7.]
H. Hosoda, M. Kojima, H. Matsuo, K. Kangawa.
Purification and characterization of rat des-Gln14-ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor.
J Biol Chem, 275 (2000), pp. 21995-22000
[8.]
C. Bowers.
Unnatural growth hormone-releasing peptide begets natural ghrelin.
J Clin Endocrinol Metab, 86 (2001), pp. 1464-1469
[9.]
H. Hosoda, M. Kojima, H. Matsuo, K. Kangawa.
Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue.
Biochem Biophy Res Comm, 279 (2000), pp. 909-913
[10.]
G. Muccioli, M. Tschöp, M. Papotti, R. Denghenghi, M. Herman, E. Ghigo.
Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity.
Eur J Pharmacol, 40 (2002), pp. 235-254
[11.]
A. Howard, S. Feighner, D. Cully, J. Arena, P. Liberator, C. Rosenblum, et al.
A receptor in pituitary and hypothalamus that functions in growth hormone release.
Science, 273 (1996), pp. 975-977
[12.]
P. Cassoni, M. Papotti, C. Ghè, F. Catapano, A. Sapino, A. Grazziani, et al.
Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines.
J Clin Endocrinol Metab, 86 (2001), pp. 1738-1745
[13.]
M. Korbonits, S. Bustin, M. Kojima, S. Jordan, E. Adams, D. Lowe, et al.
The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors.
J Clin Endocrinol Metab, 86 (2001), pp. 881-887
[14.]
E. Ghigo, E. Arvat, R. Giordano, F. Broglio, L. Gianotti, M. Maccario, et al.
Biological activities of growth hormone secretagogues in humans.
Endocrine, 14 (2001), pp. 87-93
[15.]
E. Arvat, L. Di Vito, F. Broglio, M. Papotti, G. Muccioli, C. Díeguez, et al.
Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans.
J Endocrinol Invest, 23 (2000), pp. 493-495
[16.]
R. Smith, L. Van der Ploeg, A. Howard, S. Feighner, K. Cheng, G. Hickey, et al.
Peptidomimetic regulation of growth hormone secretion.
Endocrine Rev, 18 (1997), pp. 621-645
[17.]
H. Maheshwari, A. Rahim, M. Shalet, G. Baumann.
Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency.
J Clin Endocrinol Metab, 84 (1999), pp. 956-959
[18.]
E. Arvat, R. Giordano, F. Broglio, L. Gianotti, L. Di Vito, G. Bisi, et al.
GH secretagogues in aging.
J Anti-Aging Med, 3 (2000), pp. 149-158
[19.]
V. Popovic, A. Leal, D. Micic, H.P. Koppeschaar, E. Torres, C. Páramo, et al.
GH-releasing hormone and GH-releasing peptide 6 for diagnostic testing in GH-deficient adults.
Lancet, 356 (2000), pp. 1137-1142
[20.]
M. Korbonits, R.A. Jacobs, S.J. Aylwin, J.M. Burrin, P.L. Dahia, J.P. Monson, et al.
Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
J Clin Endocrinol Metab, 83 (1998), pp. 3624-3630
[21.]
R. Smith, R. Leonard, A. Bailey, O. Palyha, S. Feighner, C. Tan, et al.
Growth hormone secretagogue receptor family members and ligands.
Endocrine, 14 (2001), pp. 9-14
[22.]
A. Asakawa, A. Inui, T. Kaga, H. Yuzuriha, T. Nagata, N. Ueno, et al.
Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin.
Gastroenterology, 120 (2001), pp. 337-345
[23.]
C. Folwaczny, J. Chang, M. Tschöp.
Ghrelin and motilin: two sides of one coin?.
Eur J Endocrinol, 144 (2001), pp. R1-R3
[24.]
Y. Masuda, T. Tanaka, N. Inomata, N. Ohnuma, S. Tanaka, Z. Itoh, et al.
Ghrelin stimulates gastric acid secretion and motility in rats.
Biochem Biophys Res Commun, 276 (2000), pp. 905-908
[25.]
Y. Date, M. Nakazato, N. Murakami, M. Kojima, K. Kangawa, S. Matsukura.
Ghrelin acts in the central nervous system to stimulate gastric acid secretion.
Biochem Biophys Res Commun, 280 (2001), pp. 904-907
[26.]
M. Tschöp, R. Wawarta, R. Riepl, S. Friedrich, M. Bidlingmaier, R. Landgraf, et al.
Post-pandrial decrease of circulating human ghrelin levels.
J Endocrinol Invest, 24 (2001), pp. RC19-RC21
[27.]
M. Papotti, C. Ghé, P. Cassoni, F. Catapano, R. Deghenghi, E. Ghigo, et al.
Growth hormone secretagogue binding sites in peripheral human tissues.
J Clin Endocrinol Metab, 85 (2000), pp. 3803-3807
[28.]
G. Muccioli, F. Broglio, M.R. Valetto, C. Ghé, F. Catapano, A. Graziani, et al.
Growth hormone-releasing peptides and the cardiovascular system.
Ann Endocrinol, 61 (2000), pp. 27-31
[29.]
N. Nagaya, M. Kojima, M. Uematsu, M. Yamagishi, H. Hosoda, H. Oya, et al.
Hemodynamic and hormonal effects of human ghrelin in healthy volunteers.
Am J Physiol Regulatory Integrative Comp Physiol, 280 (2001), pp. R1483-R1487
[30.]
N. Filigheddu, A. Fubini, G. Baldanzi, S. Cutrupi, C. Ghé, F. Catapano, et al.
Hexarelin protects H9C2 cardiomyocytes from doxorubicin-induced cell death.
Endocrine, 14 (2001), pp. 113-119
[31.]
P. Cassoni, M. Papotti, F. Catapano, C. Ghé, R. Deghenghi, E. Ghigo, et al.
Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue.
J Endocrinol, 165 (2000), pp. 139-146
[32.]
M. Tschöp, D. Smiley, M. Heiman.
Ghrelin induces adiposity in rodents.
Nature, 407 (2000), pp. 908-913
[33.]
A. Wren, C. Small, H. Ward, K. Murphy, C. Dakin, S. Taheri, et al.
The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion.
Endocrinology, 141 (2000), pp. 4325-4328
[34.]
M. Nakazato, N. Murakami, Y. Date, M. Kojima, H. Matsuo, K. Kangawa, et al.
A role for ghrelin in the central regulation of feeding.
Nature, 409 (2001), pp. 194-198
[35.]
M. Tschöp, M. Statnick, T. Suter, M. Heiman.
GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein.
Endocrinology, 143 (2002), pp. 558-568
[36.]
A.M. Wren, C.J. Small, C.R. Abbott, W.S. Dhillo, I.J. Seal le, M.A. Cohen, et al.
Ghrelin causes hyperphagia and obesity in rats.
Diabetes, 50 (2001), pp. 2540-2547
[37.]
A.M. Wren, L.J. Seal, M.A. Cohen, A.E. Brynes, G.S. Frost, K.G. Murphy, et al.
Ghrelin enhances appetite and increases food intake in humans.
J Clin Endocrinol Metab, 86 (2001), pp. 5992
[38.]
A. Sainsbury, G. Cooney, H. Herzog.
Hypothalamic regulation of energy homeostasis.
Res Clin Endocrinol Metab, 16 (2002), pp. 623-637
[39.]
M. Tschöp, C. Weyer, A. Tataranni, V. Devanarayan, E. Ravussin, M. Heiman.
Circulating ghrelin levels are decreased in human obesity.
Diabetes, 50 (2001), pp. 707-709
[40.]
D. Cummings, D. Weigle, S. Frayo, P. Breen, M. Ma, E. Dellinger, et al.
Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.
N Engl J Med, 346 (2002), pp. 1623-1632
[41.]
T. Shiiya, M. Nakazato, M. Mizuta, Y. Date, M. Mondal, M. Tanaka, et al.
Plasma ghrelin levels in lean ad obese humans and the effect of glucose on ghrelin secretion.
J Clin Endocrinol Metab, 87 (2002), pp. 240-244
[42.]
T.K. Hansen, R. Dall, H. Hosoda, M. Kojima, K. Kangawa, J.S. Christiansen, et al.
Weight loss increases circulating levels of ghrelin in human obesity.
Clin Endocrinol (Oxf), 56 (2002), pp. 203-206
[43.]
A. Caixàs, C. Bashore, W. Nash, F.X. Pi-Sunyer, B. Lafarrère.
Insulin, unlike food intake, does not supress ghrelin in human subjects.
J Clin Endocrinol Metab, 87 (2002), pp. 1902-1906
[44.]
D. Cummings, J. Purnell, R. Frayo, K. Schmidova, B. Wisse, D. Weigle.
A prepandrial rise in plasma ghrelin levels suggests a role in meal initiation in humans.
Diabetes, 50 (2001), pp. 1-6
[45.]
P.J. English, M.A. Ghatei, I.A. Malik, S.R. Bloom, J.P.H. Wilding.
Food fails to supress ghrelin levels in obese humans.
J Clin Endocrinol Metab, 87 (2002), pp. 2984-2987
[46.]
T. Hansen, R. Dall, H. Hosoda, M. Kojima, K. Kangawa, J. Chistiansen, et al.
Weight loss increases circulating levels of ghrelin in human obesity.
Clin Endocrinol (Oxf), 56 (2002), pp. 203-206
[47.]
Frühbeck G, Díez-Caballero A, Gil M J, Montero I, Gómez- Ambrosi J, Salvador J. Plasma ghrelin concentrations following bariatric surgery depend on the functional integrity of the fundus [in press]. Int J Obes.
[48.]
D.E. Cummings, M. Coupaye, R.S. Frayo, B. Guy-Grand, A. Basdevant, K. Clement.
Weight loss caused by adjustable gastric banding increases plasma ghrelin levels in humans.
85th Annual Meeting of The Endocrine Society;, (2003),
[49.]
U. Hanusch-Enserer, G. Brabant, M. Roden.
Ghrelin concentrations in morbidly obese patients after adjustable gastric banding.
N Engl J Med, 348 (2003), pp. 2159-2160
[50.]
B. Geloneze, M.A. Tambascia, V.F. Pilla, S.R. Geloneze, E.M. Repetto, J.C. Pareja.
Ghrelin: a gut-brain hormone: effect of gastric bypass surgery.
Obes Surg, 13 (2003), pp. 17-22
[51.]
N.A. Tritos, E. Mun, A. Bertkau, R. Grayson, E. Maratos-Flier, A. Goldfine.
Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery.
Obes Res, 11 (2003), pp. 919-924
[52.]
C. Holdstock, B. Engström, M. Öhrvall, L. Lind, M. Sundbom, F.A. Karlsson.
Ghrelin and adipose tissue regulatory peptides: effect of gastric by-pass surgery in obese humans.
J Clin Endocrinol Metab, 88 (2003), pp. 3177-3183
[53.]
M. Faraj, P.J. Havel, S. Phelis, D. Blank, A.D. Sniderman, K. Cianflone.
Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weigth loss induced by gastric bypass surgery in morbidly obes subjects.
J Clin Endocrinol Metab, 88 (2003), pp. 1594-1602
[54.]
D. Cummings, K. Clement, J. Purnell, C. Vaisse, K. Foster, R. Frayo, et al.
Elevated plasma ghrelin levels in Prader-Willi syndrome.
Nature, 8 (2002), pp. 643-644
[55.]
A. Haqq, S. Farooqi, S. O'Rahilly, D. Stadler, R. Rosenfeld, K. Pratt, et al.
Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome.
J Clin Endocrinol Metab, 88 (2003), pp. 174-178
[56.]
A. Delparigi, M. Tschöp, M. Heiman, A. Salbe, B. Vozarova, S. Sell, et al.
High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome.
J Clin Endocrinol Metab, 87 (2002), pp. 5461-5464
[57.]
A. Haqq, D. Stadler, R. Rosenfeld, K. Pratt, D. Weigle, R. Frayo, et al.
Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome.
J Clin Endocrinol Metab, 88 (2003), pp. 3573-3576
[58.]
H. Ariyasu, K. Takaya, T. Tagami, Y. Ogawa, S. Hosoda, T. Akamizu, et al.
Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans.
J Clin Endocrinol Metab, 86 (2001), pp. 4753-4758
[59.]
M. Tanaka, T. Naruo, T. Muranaga, D. Yasuhara, T. Shiiya, M. Nakazato, et al.
Increased fasting plasma ghrelin levels in patients with bulimia nervosa.
Eur J Endocrinol, 146 (2002), pp. R1-R3
[60.]
N. Nagaya, M. Vematsu, M. Kojima, Y. Date, M. Nakazato, H. Okumura, et al.
Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationship between ghrelin and anabolic/catabolic factors.
Circulation, 104 (2001), pp. 2034-2038
[61.]
B.E. Wise, R.S. Frayo, M.W. Schwartz, D.E. Cummings.
Reversal of cancer anorexia by blockade of central melanocortin receptors in rats.
Endocrinology, 142 (2001), pp. 3292-3301
[62.]
V. Tolle, M. Kadem, M.T. Bluet-Pajot, D. Frere, C. Foulon, C. Bossu, et al.
Equilibrio in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women.
J Clin Endocrinol Metab, 88 (2003), pp. 109-116
[63.]
J. Nedvídková, I. Krykorková, V. Barták, H. Papezová, P. Gold, S. Alesci, et al.
Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa.
J Clin Endocrinol Metab, 88 (2003), pp. 1678-1682
[64.]
B. Otto, U. Cuntz, E. Fruehauf, R. Wawarta, C. Folwaczny, R.L. Riepl, et al.
Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa.
Eur J Endocrinol, 145 (2001), pp. R5-R9
[65.]
M. Tanaka, T. Naruo, N. Nagai, N. Kuroki, T. Shiiya, M. Nakazato, et al.
Habitual binge/purge behavior influences circulating ghrelin levels in eating disorders.
J Psychiatric Res, 37 (2003), pp. 17-22
[66.]
A. Barkan, E. Dimaraki, S. Jessup, K. Symons, M. Ermolenko, C. Jaffe.
Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels.
J Clin Endocrinol Metab, 88 (2003), pp. 2180-2184
[67.]
D. Flanagan, M. Evans, T. Monsod, F. Rife, R. Heptulla, W. Tamborlane, et al.
The influence of insulin on circulating ghrelin.
Am J Physiol Endocrinol Metab, 284 (2003), pp. E313-E316
[68.]
P. Lucidi, G. Murdolo, C. Di Loreto, A. De Cicco, N. Parlanti, C. Fanelli, et al.
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglucemia.
Diabetes, 51 (2002), pp. 2911-2914
[69.]
M. Saad, B. Bernaba, C. Hwu, S. Jinagouda, S. Fahmi, E. Kogosov, et al.
Insulin regulates plasma ghrelin concentrations.
J Clin Endocrinol Metab, 87 (2002), pp. 3997-4000
[70.]
G. Schaller, A. Schmidt, J. Pleiner, W. Woloszczuk, M. Wolzt, A. Luger.
Plasma ghrelin concentrations are not regulated by glucose or insulin.
Diabetes, 52 (2003), pp. 16-20
[71.]
F. Brolgio, E. Arvat, A. Benso, C. Gottero, G. Muccioli, M. Papotti, et al.
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans.
J Clin Endocrinol Metab, 86 (2001), pp. 5083-5086
[72.]
E. Egido, J. Rodríguez-Gallardo, R. Silvestre, J. Marco.
Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion.
Eur J Endocrinol, 146 (2002), pp. 241-244
[73.]
M. Reimer, G. Pacini, B. Ahrén.
Dose-dependent inhibition by ghrelin of insulin secretion in the mouse.
Endocrinology, 144 (2003), pp. 916-921
[74.]
Y. Date, M. Nakazato, S. Hashiguchi, K. Dezaki, M. Mondal, H. Hosoda, et al.
Ghrelin is present in pancreatic cells of humans and rats and stimulates insulin secretion.
Diabetes, 51 (2002), pp. 124-129
[75.]
H. Lee, G. Wang, E. Englander, M. Kojima, G. Greeley.
Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations.
Endocrinology, 143 (2002), pp. 185-190
[76.]
E. Adeghate, A. Ponery.
Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats.
J Neuroendocrinol, 14 (2002), pp. 555-560
[77.]
P. Freda, C. Reyes, I. Conwell, R. Sundeen, S. Wardlaw.
Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
J Clin Endocrinol Metab, 88 (2003), pp. 2037-2044
[78.]
F. Tacke, G. Brabant, E. Kruck, R. Horn, P. Schöffski, H. Hecker, et al.
Ghrelin in chronic liver disease.
J Hepatol, 38 (2003), pp. 447-454
[79.]
A. Yoshimoto, K. Mori, A. Sugawara, M. Mukoyama, K. Yahata, T. Suganami, et al.
Plasma ghrelin and desacyl ghrelin concentrations in renal failure.
J Am Soc Nephrol, 13 (2002), pp. 2742-2748
[80.]
C. Schöfl, R. Horn, T. Schill, H. Schlösser, M. Müller, G. Brabant.
Circulating ghrelin levels in patients with polycystic ovary syndrome.
J Clin Endocrinol Metab, 87 (2002), pp. 4607-4610
[81.]
U. Pagotto, A. Gambineri, V. Vicennati, M. Heiman, M. Tschöp, R. Pasquali.
Plasma ghrelin, obesity, and the policystic ovary syndrome: correlation with insulin resistance and androgen levels.
J Clin Endocrinol Metab, 87 (2003), pp. 5625-5629
[82.]
M. Krsek, M. Rosická, M. Haluzík, J. Svobodová, E. Kotrlíková, V. Justová, et al.
Plasma ghrelin levels in patients with short bowel syndrome.
Endocr Res, 28 (2002), pp. 27-33
[83.]
A. Riis, T. Hansen, N. Møller, J. Weeke, J. Jørgensen.
Hyperthyroidism is associated with suppressed circulating ghrelin levels.
J Clin Endocrinol Metab, 88 (2003), pp. 853-857
[84.]
A. Gokcel, Y. Gumurdulu, F. Kayaselcuk, E. Serin, A. Ozsahin, N. Guvener.
Helicobacter pylori has no effect on plasma ghrelin levels.
Eur J Endocrinol, 48 (2003), pp. 423-426
[85.]
C.U. Nwokolo, D.A. Freshwater, P. O'Hare, H.S. Randeva.
Plasma ghrelin following cure of Helicobacter pylori.
Gut, 52 (2003), pp. 637-640
[86.]
T. Furuta, N. Shirai, F. Xiao, M. Takashima, H. Hanai.
Effect of helicobacter infection and its eradication on nutrition.
Aliment Pharmacol Ther, 4 (2002), pp. 799-806
Copyright © 2004. Sociedad Española de Endocrinología y Nutrición
